Rebecca K West1, Ramit Ravona-Springer2, James Schmeidler3, Derek Leroith3, Keren Koifman2, Elizabeth Guerrero-Berroa3, Rachel Preiss2, Hadas Hoffman2, Jeremy M Silverman4, Anthony Heymann5, Michal Schnaider-Beeri6. 1. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: rebecca.west@mssm.edu. 2. The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel. 3. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY. 4. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY; James J. Peters Veterans Affairs Medical Center, Bronx, NY. 5. Maccabi Healthcare Services, Tel-Aviv, Israel. 6. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY; The Joseph Sagol Neuroscience Center, Sheba Medical Center, Ramat Gan, Israel; Maccabi Healthcare Services, Tel-Aviv, Israel.
Abstract
OBJECTIVES: It is unclear why duration of type 2 diabetes (T2D) is associated with increased cognitive compromise. High hemoglobin A1c (HbA1c) has also been associated with dementia, and is the primary contributor to T2D complications. Here we investigated whether the association of duration of T2D with cognitive functioning is modulated by HbA1C levels. METHODS: This study examined nondemented community-dwelling T2D elderly (N = 897) participating in the Israel Diabetes and Cognitive Decline study, who were assessed with a broad neuropsychological battery. Subjects were all from the Maccabi Healthcare Services, which has a Diabetes Registry with complete HbA1c measurements since 1998. Partial correlations were performed to examine the modulating effect of HbA1c on the relationship of duration of T2D with five cognitive measures, controlling for sociodemographic and cardiovascular risk factors. RESULTS: An interaction of duration of T2D with HbA1c was associated with executive functioning (p = 0.006), semantic categorization (p = 0.019), attention/working memory (p = 0.011), and overall cognition (p = 0.006), such that the associations between duration of T2D and cognitive impairment increased as HbA1c levels increased-but not for episodic memory (p = 0.984). CONCLUSIONS: Because duration of T2D was associated with cognition in higher HbA1c levels and overall no associations were found in lower HbA1c levels, our results suggest that individuals with T2D may limit their risk of future cognitive decline by maintaining long-term good glycemic control.
OBJECTIVES: It is unclear why duration of type 2 diabetes (T2D) is associated with increased cognitive compromise. High hemoglobin A1c (HbA1c) has also been associated with dementia, and is the primary contributor to T2D complications. Here we investigated whether the association of duration of T2D with cognitive functioning is modulated by HbA1C levels. METHODS: This study examined nondemented community-dwelling T2D elderly (N = 897) participating in the Israel Diabetes and Cognitive Decline study, who were assessed with a broad neuropsychological battery. Subjects were all from the Maccabi Healthcare Services, which has a Diabetes Registry with complete HbA1c measurements since 1998. Partial correlations were performed to examine the modulating effect of HbA1c on the relationship of duration of T2D with five cognitive measures, controlling for sociodemographic and cardiovascular risk factors. RESULTS: An interaction of duration of T2D with HbA1c was associated with executive functioning (p = 0.006), semantic categorization (p = 0.019), attention/working memory (p = 0.011), and overall cognition (p = 0.006), such that the associations between duration of T2D and cognitive impairment increased as HbA1c levels increased-but not for episodic memory (p = 0.984). CONCLUSIONS: Because duration of T2D was associated with cognition in higher HbA1c levels and overall no associations were found in lower HbA1c levels, our results suggest that individuals with T2D may limit their risk of future cognitive decline by maintaining long-term good glycemic control.
Authors: Michal Schnaider Beeri; Jeremy M Silverman; Kenneth L Davis; Deborah Marin; Hillel Z Grossman; James Schmeidler; Dushyant P Purohit; Daniel P Perl; Michael Davidson; Richard C Mohs; Vahram Haroutunian Journal: J Gerontol A Biol Sci Med Sci Date: 2005-04 Impact factor: 6.053
Authors: Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; James Schmeidler; Jeremy M Silverman; Mary Sano; Keren Koifmann; Rachel Preiss; Hadas Hoffman; Anthony Heymann; Michal Schnaider Beeri Journal: Int J Geriatr Psychiatry Date: 2013-08-08 Impact factor: 3.485
Authors: Niels D Prins; Ewoud J van Dijk; Tom den Heijer; Sarah E Vermeer; Jellemer Jolles; Peter J Koudstaal; Albert Hofman; Monique M B Breteler Journal: Brain Date: 2005-06-09 Impact factor: 13.501
Authors: Linda B Hassing; Michael D Grant; Scott M Hofer; Nancy L Pedersen; Sven E Nilsson; Stig Berg; Gerald McClearn; Boo Johansson Journal: J Int Neuropsychol Soc Date: 2004-07 Impact factor: 2.892
Authors: Jane S Saczynski; María K Jónsdóttir; Melissa E Garcia; Palmi V Jonsson; Rita Peila; Gudny Eiriksdottir; Elin Olafsdottir; Tamara B Harris; Vilmundur Gudnason; Lenore J Launer Journal: Am J Epidemiol Date: 2008-10-03 Impact factor: 4.897
Authors: Calliope Holingue; Alexandra Wennberg; Slava Berger; Vsevolod Y Polotsky; Adam P Spira Journal: Metabolism Date: 2018-02-01 Impact factor: 8.694
Authors: Josephine Mollon; Joanne E Curran; Samuel R Mathias; Emma E M Knowles; Phoebe Carlisle; Peter T Fox; Rene L Olvera; Harald H H Göring; Amanda Rodrigue; Laura Almasy; Ravi Duggirala; John Blangero; David C Glahn Journal: Diabetologia Date: 2020-02-04 Impact factor: 10.122
Authors: Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Andrew Levy; Derek Leroith; Michal S Beeri Journal: Diabetologia Date: 2015-01-28 Impact factor: 10.122
Authors: M M Lauridsen; L Poulsen; C K Rasmussen; M Høgild; M K Nielsen; O B Schaffalitzky de Muckadell; H Vilstrup Journal: Metab Brain Dis Date: 2015-10-05 Impact factor: 3.584
Authors: Jimmy Akrivos; Ramit Ravona-Springer; James Schmeidler; Derek LeRoith; Anthony Heymann; Rachel Preiss; Hadas Hoffman; Keren Koifman; Jeremy M Silverman; Michal Schnaider Beeri Journal: Int J Geriatr Psychiatry Date: 2015-02-20 Impact factor: 3.485
Authors: Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Hadas Hoffman; Rachel Preiss; Keren Koifmann; Lior Greenbaum; Andrew Levy; Jeremy M Silverman; Derek Leroith; Mary Sano; Michal Schnaider-Beeri Journal: Int J Geriatr Psychiatry Date: 2015-09-21 Impact factor: 3.485
Authors: Rebecca K West; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Derek Leroith; Keren Koifman; Ryan C N D'Arcy; Xiaowei Song; Elizabeth Guerrero-Berroa; Rachel Preiss; Hadas Hoffman; Mary Sano; Jeremy M Silverman; Michal Schnaider-Beeri Journal: Alzheimers Dement Date: 2016-05-02 Impact factor: 21.566